ViroPharma (VPHM +2.6%) gains after releasing positive results from trials of its Cinryze, a...
ViroPharma (VPHM +2.6%) gains after releasing positive results from trials of its Cinryze, a therapy approved for routine prevention of angioedema attacks in patients with hereditary forms of the disease. The study showed a 54.7% decrease in attack rate for those patients treated with Cinryze over the period, which is similar to the reduction in attack rate (52%) from the overall study population.
From other sites
at Investor's Business Daily (Feb 12, 2015)
at Investor's Business Daily (Jan 26, 2015)
at CNBC.com (Jan 16, 2015)
at CNBC.com (Jan 15, 2015)
at Benzinga.com (Jan 15, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs